On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -11.11% from the last session, before settling in for the closing price of $2.16. Price fluctuations for ZNTL have ranged from $1.61 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 44.78% at the time writing. With a float of $54.45 million, this company’s outstanding shares have now reached $71.15 million.
Let’s look at the performance matrix of the company that is accounted for 168 employees. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 23.44%, while institutional ownership is 84.25%. The most recent insider transaction that took place on Feb 03 ’25, was worth 4,476. In this transaction PAO and Interim PFO of this company sold 2,615 shares at a rate of $1.71, taking the stock ownership to the 189,826 shares. Before that another transaction happened on Feb 03 ’25, when Company’s Chief Scientific Officer sold 14,368 for $1.71, making the entire transaction worth $24,591. This insider now owns 512,856 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.78% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.67% during the next five years compared to -50.05% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) saw its 5-day average volume 2.8 million, a negative change from its year-to-date volume of 2.9 million. As of the previous 9 days, the stock’s Stochastic %D was 50.92%. Additionally, its Average True Range was 0.29.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 8.09%, which indicates a significant decrease from 34.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 175.98% in the past 14 days, which was higher than the 109.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.8318, while its 200-day Moving Average is $4.8964. Nevertheless, the first resistance level for the watch stands at $2.1433 in the near term. At $2.3667, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.4833. If the price goes on to break the first support level at $1.8033, it is likely to go to the next support level at $1.6867. The third support level lies at $1.4633 if the price breaches the second support level.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,265K shares outstanding in the company with a market cap of 136.83 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -88,280 K.
